Skip to main content

2020 | OriginalPaper | Buchkapitel

SPOC: Identification of Drug Targets in Biological Networks via Set Preference Output Control

verfasst von : Hao Gao, Min Li, Fang-Xiang Wu

Erschienen in: Bioinformatics Research and Applications

Verlag: Springer International Publishing

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

Biological networks describe the relationships among molecular elements and help in the deep understanding of the biological mechanisms and functions. One of the common problems is to identify the set of biomolecules that could be targeted by drugs to drive the state transition of the cells from disease states to health states called desired states as the realization of the therapy of complex diseases. Most previous studies based on the output control determine the set of steering nodes without considering available biological information. In this study, we propose a strategy by using the additionally available information like the FDA-approved drug targets to restrict the range for choosing steering nodes in output control instead, where we call it the Set Preference Output Control (SPOC) problem. A graphic-theoretic algorithm is proposed to approximately tackle it by using the Maximum Weighted Complete Matching (MWCM). The computation experiment results from two biological networks illustrate that our proposed SPOC strategy outperforms the full control and output control strategies to identify drug targets. Finally, the case studies further demonstrate the role of the combination therapy in two biological networks, which reveals that our proposed SPOC strategy is potentially applicable for more complicated cases.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 340 Zeitschriften

aus folgenden Fachgebieten:

  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Versicherung + Risiko




Jetzt Wissensvorsprung sichern!

Literatur
1.
Zurück zum Zitat Barabási, A.L., et al.: Network Science. Cambridge University Press, Cambridge (2016) Barabási, A.L., et al.: Network Science. Cambridge University Press, Cambridge (2016)
2.
Zurück zum Zitat Barabási, A.L., Gulbahce, N., Loscalzo, J.: Network medicine: a network-based approach to human disease. Nat. Rev. Genet. 12(1), 56 (2011)PubMedPubMedCentral Barabási, A.L., Gulbahce, N., Loscalzo, J.: Network medicine: a network-based approach to human disease. Nat. Rev. Genet. 12(1), 56 (2011)PubMedPubMedCentral
3.
Zurück zum Zitat Jeong, H., Mason, S.P., Barabási, A.L., Oltvai, Z.N.: Lethality and centrality in protein networks. Nature 411(6833), 41 (2001)PubMed Jeong, H., Mason, S.P., Barabási, A.L., Oltvai, Z.N.: Lethality and centrality in protein networks. Nature 411(6833), 41 (2001)PubMed
4.
Zurück zum Zitat Winzeler, E.A., et al.: Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science 285(5429), 901–906 (1999)PubMed Winzeler, E.A., et al.: Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science 285(5429), 901–906 (1999)PubMed
5.
Zurück zum Zitat Zeng, M., Zhang, F., Wu, F.X., Li, Y., Wang, J., Li, M.: Protein-protein interaction site prediction through combining local and global features with deep neural networks. Bioinformatics 36(4), 1114–1120 (2020)PubMed Zeng, M., Zhang, F., Wu, F.X., Li, Y., Wang, J., Li, M.: Protein-protein interaction site prediction through combining local and global features with deep neural networks. Bioinformatics 36(4), 1114–1120 (2020)PubMed
6.
Zurück zum Zitat Li, M., Gao, H., Wang, J., Wu, F.X.: Control principles for complex biological networks. Brief. Bioinform. 20(6), 2253–2266 (2019)PubMed Li, M., Gao, H., Wang, J., Wu, F.X.: Control principles for complex biological networks. Brief. Bioinform. 20(6), 2253–2266 (2019)PubMed
7.
Zurück zum Zitat Guo, W.F., Zhang, S.W., Zeng, T., Akutsu, T., Chen, L.: Network control principles for identifying personalized driver genes in cancer. Brief. Bioinform. (2019) Guo, W.F., Zhang, S.W., Zeng, T., Akutsu, T., Chen, L.: Network control principles for identifying personalized driver genes in cancer. Brief. Bioinform. (2019)
8.
Zurück zum Zitat Liu, Y.Y., Slotine, J.J., Barabási, A.L.: Controllability of complex networks. Nature 473(7346), 167 (2011)PubMed Liu, Y.Y., Slotine, J.J., Barabási, A.L.: Controllability of complex networks. Nature 473(7346), 167 (2011)PubMed
9.
Zurück zum Zitat Wu, L., Shen, Y., Li, M., Wu, F.X.: Network output controllability-based method for drug target identification. IEEE Trans. Nanobiosci. 14(2), 184–191 (2015) Wu, L., Shen, Y., Li, M., Wu, F.X.: Network output controllability-based method for drug target identification. IEEE Trans. Nanobiosci. 14(2), 184–191 (2015)
10.
Zurück zum Zitat Gao, J., Liu, Y.Y., D’souza, R.M., Barabási, A.L.: Target control of complex networks. Nat. Commun. 5, 5415 (2014)PubMedPubMedCentral Gao, J., Liu, Y.Y., D’souza, R.M., Barabási, A.L.: Target control of complex networks. Nat. Commun. 5, 5415 (2014)PubMedPubMedCentral
11.
Zurück zum Zitat Wu, L., Li, M., Wang, J., Wu, F.X.: Minimum steering node set of complex networks and its applications to biomolecular networks. IET Syst. Biol. 10(3), 116–123 (2016)PubMed Wu, L., Li, M., Wang, J., Wu, F.X.: Minimum steering node set of complex networks and its applications to biomolecular networks. IET Syst. Biol. 10(3), 116–123 (2016)PubMed
12.
Zurück zum Zitat Guo, W.F., et al.: Discovering personalized driver mutation profiles of single samples in cancer by network control strategy. Bioinformatics 34(11), 1893–1903 (2018)PubMed Guo, W.F., et al.: Discovering personalized driver mutation profiles of single samples in cancer by network control strategy. Bioinformatics 34(11), 1893–1903 (2018)PubMed
13.
Zurück zum Zitat Hu, Y., et al.: Optimal control nodes in disease-perturbed networks as targets for combination therapy. Nat. Commun. 10(1), 2180 (2019)PubMedPubMedCentral Hu, Y., et al.: Optimal control nodes in disease-perturbed networks as targets for combination therapy. Nat. Commun. 10(1), 2180 (2019)PubMedPubMedCentral
14.
Zurück zum Zitat Wu, L., Tang, L., Li, M., Wang, J., Wu, F.X.: Biomolecular network controllability with drug binding information. IEEE Trans. Nanobiosci. 16(5), 326–332 (2017) Wu, L., Tang, L., Li, M., Wang, J., Wu, F.X.: Biomolecular network controllability with drug binding information. IEEE Trans. Nanobiosci. 16(5), 326–332 (2017)
15.
Zurück zum Zitat Guo, W.F., et al.: Constrained target controllability of complex networks. J. Stat. Mech: Theory Exp. 2017(6), 063402 (2017) Guo, W.F., et al.: Constrained target controllability of complex networks. J. Stat. Mech: Theory Exp. 2017(6), 063402 (2017)
16.
Zurück zum Zitat Müller, F.J., Schuppert, A.: Few inputs can reprogram biological networks. Nature 478(7369), E4 (2011)PubMed Müller, F.J., Schuppert, A.: Few inputs can reprogram biological networks. Nature 478(7369), E4 (2011)PubMed
17.
Zurück zum Zitat Kailath, T.: Linear Systems, vol. 156. Prentice-Hall, Englewood Cliffs (1980) Kailath, T.: Linear Systems, vol. 156. Prentice-Hall, Englewood Cliffs (1980)
18.
Zurück zum Zitat Lin, C.T.: Structural controllability. IEEE Trans. Autom. Control 19(3), 201–208 (1974) Lin, C.T.: Structural controllability. IEEE Trans. Autom. Control 19(3), 201–208 (1974)
20.
Zurück zum Zitat Crouse, D.F.: On implementing 2D rectangular assignment algorithms. IEEE Trans. Aerosp. Electron. Syst. 52(4), 1679–1696 (2016) Crouse, D.F.: On implementing 2D rectangular assignment algorithms. IEEE Trans. Aerosp. Electron. Syst. 52(4), 1679–1696 (2016)
21.
Zurück zum Zitat Grieco, L., Calzone, L., Bernard-Pierrot, I., Radvanyi, F., Kahn-Perles, B., Thieffry, D.: Integrative modelling of the influence of mapk network on cancer cell fate decision. PLoS Comput. Biol. 9(10), e1003286 (2013)PubMedPubMedCentral Grieco, L., Calzone, L., Bernard-Pierrot, I., Radvanyi, F., Kahn-Perles, B., Thieffry, D.: Integrative modelling of the influence of mapk network on cancer cell fate decision. PLoS Comput. Biol. 9(10), e1003286 (2013)PubMedPubMedCentral
22.
Zurück zum Zitat Wishart, D.S., et al.: Drugbank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 36(suppl–1), D901–D906 (2007)PubMedPubMedCentral Wishart, D.S., et al.: Drugbank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 36(suppl–1), D901–D906 (2007)PubMedPubMedCentral
24.
Zurück zum Zitat Lafitte, M., et al.: FGFR3 has tumor suppressor properties in cells with epithelial phenotype. Mol. Cancer 12(1), 83 (2013)PubMedPubMedCentral Lafitte, M., et al.: FGFR3 has tumor suppressor properties in cells with epithelial phenotype. Mol. Cancer 12(1), 83 (2013)PubMedPubMedCentral
25.
Zurück zum Zitat Sigismund, S., Avanzato, D., Lanzetti, L.: Emerging functions of the EGFR in cancer. Mol. Oncol. 12(1), 3–20 (2018)PubMed Sigismund, S., Avanzato, D., Lanzetti, L.: Emerging functions of the EGFR in cancer. Mol. Oncol. 12(1), 3–20 (2018)PubMed
26.
Zurück zum Zitat Vleugel, M.M., Greijer, A.E., Bos, R., van der Wall, E., van Diest, P.J.: c-jun activation is associated with proliferation and angiogenesis in invasive breast cancer. Hum. Pathol. 37(6), 668–674 (2006)PubMed Vleugel, M.M., Greijer, A.E., Bos, R., van der Wall, E., van Diest, P.J.: c-jun activation is associated with proliferation and angiogenesis in invasive breast cancer. Hum. Pathol. 37(6), 668–674 (2006)PubMed
27.
Zurück zum Zitat Raimondi, C., Falasca, M.: Targeting PDK1 in cancer. Curr. Med. Chem. 18(18), 2763–2769 (2011)PubMed Raimondi, C., Falasca, M.: Targeting PDK1 in cancer. Curr. Med. Chem. 18(18), 2763–2769 (2011)PubMed
29.
Zurück zum Zitat Eischen, C., Adams, C., Clark-Garvey, S., Porcu, P.: Targeting the Bcl-2 family in B cell lymphoma. Front. Oncol. 8, 636 (2018)PubMed Eischen, C., Adams, C., Clark-Garvey, S., Porcu, P.: Targeting the Bcl-2 family in B cell lymphoma. Front. Oncol. 8, 636 (2018)PubMed
30.
Zurück zum Zitat Zou, M., et al.: Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790m mutation. Int. J. Oncol. 42(6), 2094–2102 (2013)PubMed Zou, M., et al.: Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790m mutation. Int. J. Oncol. 42(6), 2094–2102 (2013)PubMed
31.
Zurück zum Zitat Royce, M.E., Osman, D.: Everolimus in the treatment of metastatic breast cancer. Breast Cancer: Basic Clin. Res. 9, BCBCR–S29268 (2015) Royce, M.E., Osman, D.: Everolimus in the treatment of metastatic breast cancer. Breast Cancer: Basic Clin. Res. 9, BCBCR–S29268 (2015)
32.
Zurück zum Zitat Kornblum, N., et al.: Randomized phase ii trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy: results of pre0102. ASCO (2018) Kornblum, N., et al.: Randomized phase ii trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy: results of pre0102. ASCO (2018)
33.
Zurück zum Zitat Piha-Paul, S.A., et al.: Phase i study of the pan-HER inhibitor neratinib given in combination with everolimus, palbociclib or trametinib in advanced cancer subjects with EGFR mutation/amplification, HER2 mutation/amplification or HER3/4 mutation (2018) Piha-Paul, S.A., et al.: Phase i study of the pan-HER inhibitor neratinib given in combination with everolimus, palbociclib or trametinib in advanced cancer subjects with EGFR mutation/amplification, HER2 mutation/amplification or HER3/4 mutation (2018)
Metadaten
Titel
SPOC: Identification of Drug Targets in Biological Networks via Set Preference Output Control
verfasst von
Hao Gao
Min Li
Fang-Xiang Wu
Copyright-Jahr
2020
DOI
https://doi.org/10.1007/978-3-030-57821-3_3